Related Experiment Video

Updated: Feb 5, 2026

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies
04:47

A Method to Assess Fc-mediated Effector Functions Induced by Influenza Hemagglutinin Specific Antibodies

Published on: February 23, 2018

8.2K

Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity

Christian Kellner1, Stefanie Derer2, Katja Klausz1

  • 1Division of Stem Cell Transplantation and Immunotherapy, Department of Medicine II, University Hospital Schleswig-Holstein and Christian-Albrechts, University of Kiel, Kiel, Germany.

Methods in Molecular Biology (Clifton, N.J.)
|September 10, 2018
PubMed

Insights

Next-generation monoclonal antibodies utilize Fc-engineering to enhance Fc-mediated effector functions, improving cancer therapy efficacy. These engineered antibodies aim to overcome limitations of current antibody treatments for better patient outcomes.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Monoclonal antibodies are standard cancer treatments.
  • Not all patients respond effectively to current antibody therapies.
  • Fc-mediated effector mechanisms are crucial for antitumor activity.

Purpose of the Study:

  • To explore the potential of Fc-engineering technologies.
  • To improve Fc-mediated effector functions of monoclonal antibodies.
  • To overcome limitations in current antibody-based cancer therapy.

Main Methods:

  • Designing next-generation monoclonal antibodies with improved effector functions.
  • Utilizing Fc-engineering technologies to fine-tune antibody functions.
  • Evaluating mechanisms like antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, and complement-dependent cytotoxicity (CDC).

Main Results:

  • Fc-engineering allows for tailored optimization of Fc-mediated effector functions.
  • Enhanced effector functions are critical for potent antitumor responses.
  • Fc-engineered antibodies show promise in addressing current therapy limitations.

Conclusions:

  • Fc-engineering represents a significant advancement in antibody therapy design.
  • Optimized Fc-mediated functions can lead to more effective cancer treatments.
  • Future antibody therapies may leverage Fc-engineering for improved clinical benefit.
Keywords:
ADCCAntibody engineeringCDC

More Related Videos

Isolation and Characterization Of Chimeric Human Fc-expressing Proteins Using Protein A Membrane Adsorbers And A Streamlined Workflow10:33

Isolation and Characterization Of Chimeric Human Fc-expressing Proteins Using Protein A Membrane Adsorbers And A Streamlined Workflow

Published on: January 8, 2014

7.6K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.3K

Related Concept Videos

Histone Variants at the Centromere02:30

Histone Variants at the Centromere

Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
5.1K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.8K
What is Genetic Engineering?00:49

What is Genetic Engineering?

Overview
80.3K
Activation and Inactivation of G Proteins01:22

Activation and Inactivation of G Proteins

Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high...
11.5K
Group Design02:01

Group Design

The most basic experimental design involves two groups: the experimental group and the control group. The two groups are designed to be the same except for one difference— experimental manipulation. The experimental group gets the experimental manipulation—that is, the treatment or variable being tested—and the control group does not. Since experimental manipulation is the only difference between the experimental and control groups, we can be sure that any differences between...
10.6K
Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
65.6K